SLS - SELLAS Life Sciences Group, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
2.08 0.15 (7.21%) 0.0 (0.0%) 0.02 (0.9%) 0.04 (1.82%) 0.06 (2.88%) 0.02 (0.7%) 0.05 (2.32%) 0.05 (2.32%)

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: Closed

Earnings & Ratios

Basic EPS:
-0.07
Diluted EPS:
-0.07
Basic P/E:
-31.8571
Diluted P/E:
-31.8571
RSI(14) 1m:
100.0
VWAP:
2.23
RVol:

Events

Period Kind Movement Occurred At

Related News